Search results for " Modality"

showing 10 items of 461 documents

Sensory Processing in Children with Autism Spectrum Disorder and/or Attention Deficit Hyperactivity Disorder in the Home and Classroom Contexts.

2017

Children with neurodevelopmental disorders often show impairments in sensory processing (SP) and higher functions. The main objective of this study was to compare SP, praxis and social participation (SOC) in four groups of children: ASD Group (n = 21), ADHD Group (n = 21), ASD+ADHD Group (n = 21), and Comparison Group (n = 27). Participants were the parents and teachers of these children who were 5-8 years old (M = 6.32). They completed the Sensory Processing Measure (SPM) to evaluate the sensory profile, praxis and SOC of the children in both the home and classroom contexts. In the home context, the most affected was the ASD+ADHD group. The ADHD group obtained higher scores than the ASD gr…

Sensory processingmedicine.medical_treatmentlcsh:BF1-990Context (language use)Body awarenessbehavioral disciplines and activitiesDevelopmental psychology03 medical and health sciencesAutism Spectrum Disorder (ASD)0302 clinical medicineStimulus modalityIntervention (counseling)mental disordersmedicineAttention deficit hyperactivity disorderPsychology0501 psychology and cognitive scienceshome and classroom contextshigher functionssensory processingGeneral PsychologySensory Processing Measure (SPM)Original ResearchAttention Deficit/Hyperactivity Disorder (ADHD)05 social sciencesmedicine.diseaseSocial engagementlcsh:PsychologyAutism spectrum disorderPsychology030217 neurology & neurosurgery050104 developmental & child psychologyFrontiers in psychology
researchProduct

Epistemic uses of the verb decir in La Paz Spanish Digamos and dice

2017

This paper explores semantic extensions and pragmatic functions of two evidential forms found in La Paz Spanish, digamos ‘let’s say’ and dice ‘s/he says’. Both forms are inflected forms of the verb decir ‘to say’. The form dice ‘s/he says’ has the function of a reported evidential form, conforming to results from previous studies (Babel 2009; Olbertz 2007; Travis 2006; Laprade 1981), while the form digamos is used according to a previously unnoticed function of an inferential evidential.

Settore L-LIN/07 - Lingua E Traduzione - Lingua Spagnolaindirect evidentiality epistemic modality stance grammaticalizationSettore L-LIN/01 - Glottologia E Linguistica
researchProduct

Cognitive rehabilitation of schizophrenia through NeuroVr training.

2013

Cognitive difficulties are prevalent in people with diagnosis of schizophrenia and are associated with poor long-term functioning. In particular, memory, selective, divided and sustained attention and executive functions are altered by this disease. We used a Virtual Reality environment (developed via the NeuroVr2.0 software) for the rehabilitation of shifting, sustained attention and action planning functions using tasks reminiscent of daily life tasks. Test and retest showed significant differences in the assessed cognitive dimensions.

Settore M-PSI/02 - Psicobiologia E Psicologia FisiologicaCognitive Behavioral TherapyVirtual Reality Exposure TherapyVirtual RealityBiofeedback PsychologyCombined Modality TherapyCognitive RehabilitationTreatment OutcomeExecutive functionSettore M-PSI/08 - Psicologia ClinicaTherapy Computer-AssistedSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.SchizophreniaHumansSettore MED/25 - PsichiatriaSoftwareStudies in health technology and informatics
researchProduct

Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly…

2016

Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and Methods: Inclusion criteria of this prospective study were age ≥70 years, Karnofsky performance status 70 to 100, locally advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was 40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 mo…

Simultaneous integrated boostMalemedicine.medical_specialtyCancer ResearchBrachytherapyUterine Cervical NeoplasmsVMATelderly patients030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineWeekly cisplatinmedicineArc therapyHumansAgedCervical cancerRadical treatmentAged 80 and overbusiness.industryRadiotherapy DosageArticlesmedicine.diseaseVolumetric modulated arc therapyCombined Modality TherapySurgeryOncology030220 oncology & carcinogenesisCarcinoma Squamous CellVMAT; advanced cervical cancer; elderly patients; gynecological malignanciesFemaleadvanced cervical cancer; elderly patients; gynecological malignancies; VMAT; Oncology; Cancer ResearchRadiologyDose Fractionation RadiationLymph NodesRadiotherapy Intensity-ModulatedCisplatinbusinessgynecological malignanciesadvanced cervical cancer
researchProduct

Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update

2020

CTLA-4 and PD-1 play a key role in tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti-CTLA-4 and anti-PD-1 antibodies affect the interaction between tumor, antigen-presenting cells and T lymphocytes. Clinical studies of the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five-year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with …

Skin NeoplasmsDrug-Related Side Effects and Adverse ReactionsSide effectProgrammed Cell Death 1 ReceptorMedizinIpilimumabDermatologyPembrolizumabAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenImmune Checkpoint InhibitorsMelanomabusiness.industryMelanomamedicine.diseaseCombined Modality TherapyIpilimumabImmune checkpoint3. Good healthNivolumabCTLA-4ImmunologyImmunotherapyNivolumabbusinessmedicine.drug
researchProduct

Multimodal approaches to the treatment of hepatocellular carcinoma.

2008

The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis. Surveillance programs for patients with cirrhosis aim to detect tumors at an early stage, when the greatest therapeutic benefits can be achieved. Curative treatments for early-stage tumors include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib can improve survival for patients with intermediate and advanced tumors, respectively. In clinical practice, combination therapies are often used, despite limited evidence to support this approach from randomized controlled trials. Combina…

SorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularCombination therapyWaiting ListsRadiofrequency ablationPyridinesmedicine.medical_treatmentSalvage therapyAntineoplastic AgentsLiver transplantationlaw.inventionInjectionslawPreoperative CaremedicineCombined Modality TherapyHumansChemoembolization TherapeuticSalvage TherapyHepatologyEthanolbusiness.industryepatocarcinoma cirrosi HBV HCVPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseCombined Modality TherapyEmbolization TherapeuticSurgeryLiver TransplantationHepatocellular carcinomaCatheter AblationRadiotherapy AdjuvantRadiologyPercutaneous ethanol injectionbusinessmedicine.drugNature clinical practice. Gastroenterologyhepatology
researchProduct

Future perspectives in hepatocellular carcinoma.

2010

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefits have been available in up to 70% of patients. However, major progress has been achieved with regard to surveillance, early diagnosis, and multimodal treatment approaches during the last years leading to an improvement in prognosis. Particularly, the increasing knowledge of molecular hepatocarcinogenesis today provides the opportunity for targeted therapy. The multikinase inhibitor sorafenib has broadened the therapeutic horizon for patients with advanced disease and is current…

SorafenibOncologyAblation Techniquesmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationGastroenterologyTargeted therapyInternal medicinemedicineAdjuvant therapyCombined Modality TherapyHumansChemoembolization TherapeuticPrecision MedicineTranscatheter arterial chemoembolizationProtein Kinase InhibitorsHepatologybusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseCombined Modality TherapyFibrosisLiver TransplantationHepatocellular carcinomaPersonalized medicinebusinessmedicine.drugForecastingDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Recurrence of hepatocellular carcinoma after liver transplantation: an update.

2015

Liver transplantation is the only curative alternative for selected patients with hepatocellular carcinoma (HCC) who are not eligible for resection and/or with decompensated cirrhosis. According to Milan criteria the 5-year survival rate is 70–85%, with a recurrence-free survival of 75%. However, HCC recurrence rate after liver transplantation remains a significant problem in the clinical practice. The prognosis in patients with HCC recurrence is poor. The treatment of choice for HCC recurrence is surgery, but it seems that a systemic treatment based on combination of an mTOR inhibitor with sorafenib can be used. Data on safety and efficacy are limited, clinical monitoring is necessary. Th…

SorafenibOncologyCancer Researchmedicine.medical_specialtyrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentliving donorLiver transplantationMilan criteriaGastroenterologyLeukocyte CountRisk FactorsInternal medicinemedicineBiomarkers TumorCombined Modality TherapyHumansalpha-FetoproteinPerioperative PeriodSurvival rateimmunosuppressionbusiness.industryRisk FactorLiver NeoplasmsImmunosuppressionGeneral MedicinePerioperativehepatocellular carcinomamedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationTumor BurdenOncologyLiver NeoplasmHepatocellular carcinomaalpha-FetoproteinsNeoplasm Recurrence Localbusinessmedicine.drugHumanFuture oncology (London, England)
researchProduct

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

2015

According to the guidelines of the European Association for the Study of the Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clinic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in five stages (0, A, B, C and D) on the basis of a number of prognostic and treatment- related variables such as tumor status and liver function. A specific treat ment approach is then proposed for each of the above-mentioned stages. Transarterial chemoembolization (TACE) is recommended as first-line therapy in the treatment of patients with intermediate-stage (BCLC-B class) HCC [1]. The efficacy of this procedure…

SorafenibOncologyNiacinamideCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyHCC; TACE; combination therapy; intermediate stage; sorafenibAntineoplastic Agentscombination therapyInternal medicineMedicineHumansStage (cooking)Chemoembolization TherapeuticHCCProtein Kinase InhibitorsTACEintermediate stagePerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsGeneral Medicinemedicine.diseaseCombined Modality Therapydigestive system diseasesPortal vein thrombosisSurgeryOncologyHepatocellular carcinomasorafenibLiver functionbusinessLiver cancermedicine.drug
researchProduct

Surgical treatment of solitary sternal metastasis from breast cancer Case report

2016

Bone metastasis is a frequent and early complication of breast cancer. This case report describes a technique for a partial exeresis of the sternum and the reconstruction of the pleura with autologous dermis from the lower abdomen and the loss of substance with a myocutaneous flap.We describe the case of a 50-year old woman with a sternal excavated lesion with pathologic fracture due to an invasive adenocarcinoma, treated with a partial exeresis of the sternum and the reconstruction with a myocutaneous flap.The patient doesn't show evidence of recurrent disease and the stability of her chest well preserved.Metastatic breast cancer to the sternum, if detected early and treated aggressively, …

SternumSettore MED/21 - Chirurgia ToracicaCytarabineBreast cancer Sternal metastasis SternectomyBone NeoplasmsBreast NeoplasmsAdenocarcinomaMiddle AgedCombined Modality TherapyMyocutaneous FlapSettore MED/18 - Chirurgia GeneraleFractures SpontaneousAntineoplastic Combined Chemotherapy ProtocolsHumansPleuraFemaleCyclophosphamideEpirubicin
researchProduct